Devin Whittemore Smith - Net Worth and Insider Trading

Devin Whittemore Smith Net Worth

The estimated net worth of Devin Whittemore Smith is at least $26,386 dollars as of 2024-11-13. Devin Whittemore Smith is the SVP and General Counsel of Yumanity Therapeutics Inc and owns about 13,961 shares of Yumanity Therapeutics Inc (YMTX) stock worth over $26,386. Details can be seen in Devin Whittemore Smith's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Devin Whittemore Smith has not made any transactions after 2022-12-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Devin Whittemore Smith

Devin Whittemore Smith Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Devin Whittemore Smith owns 4 companies in total, including Minerva Neurosciences Inc (NERV) , Yumanity Therapeutics Inc (YMTX) , and IO Biotech Inc (IOBT) among others .

Click here to see the complete history of Devin Whittemore Smith’s form 4 insider trades.

Insider Ownership Summary of Devin Whittemore Smith

Ticker	Comapny	Transaction Date	Type of Owner
NERV	Minerva Neurosciences Inc	2018-07-23	SVP and General Counsel
YMTX	Yumanity Therapeutics Inc	2022-12-02	SVP and General Counsel
IOBT	IO Biotech Inc	2023-08-09	General Counsel
		2021-06-14	SVP and General Counsel

Devin Whittemore Smith Latest Holdings Summary

Devin Whittemore Smith currently owns a total of 1 stock. Devin Whittemore Smith owns 13,961 shares of Yumanity Therapeutics Inc (YMTX) as of December 2, 2022, with a value of $26,386.

Latest Holdings of Devin Whittemore Smith

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
YMTX	Yumanity Therapeutics Inc	2022-12-02	13,961	1.89	26,386

Holding Weightings of Devin Whittemore Smith

Devin Whittemore Smith Form 4 Trading Tracker

According to the SEC Form 4 filings, Devin Whittemore Smith has made a total of 2 transactions in Yumanity Therapeutics Inc (YMTX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Yumanity Therapeutics Inc is the sale of 3,116 shares on December 2, 2022, which brought Devin Whittemore Smith around $5,266.

Insider Trading History of Devin Whittemore Smith

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Devin Whittemore Smith Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Devin Whittemore Smith Ownership Network

Ownership Network List of Devin Whittemore Smith

No Data

Ownership Network Relation of Devin Whittemore Smith

Devin Whittemore Smith Owned Company Details

What does Minerva Neurosciences Inc do?

Who are the key executives at Minerva Neurosciences Inc?

Devin Whittemore Smith is the SVP and General Counsel of Minerva Neurosciences Inc. Other key executives at Minerva Neurosciences Inc include 10 percent owner Ag Boehringer , 10 percent owner Boehringer Ingelheim International Gmbh , and EVP and Head of R&D Remy Luthringer .

Minerva Neurosciences Inc (NERV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Minerva Neurosciences Inc (NERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Minerva Neurosciences Inc (NERV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Minerva Neurosciences Inc (NERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Minerva Neurosciences Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Devin Whittemore Smith is the SVP and General Counsel of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does IO Biotech Inc do?

Who are the key executives at IO Biotech Inc?

Devin Whittemore Smith is the General Counsel of IO Biotech Inc. Other key executives at IO Biotech Inc include 10 percent owner Novo Holdings A/s , Chief Accounting Officer Brian Burkavage , and 10 percent owner Vivo Opportunity, Llc .

IO Biotech Inc (IOBT) Insider Trades Summary

Over the past 18 months, Devin Whittemore Smith made no insider transaction in IO Biotech Inc (IOBT). Other recent insider transactions involving IO Biotech Inc (IOBT) include a net purchase of 1,076,517 shares made by Novo Holdings A/s , a net purchase of 3,157,894 shares made by Vivo Capital Fund Ix, L.p. , and a net purchase of 10,000 shares made by Brian Burkavage .

In summary, during the past 3 months, insiders sold 0 shares of IO Biotech Inc (IOBT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,392,618 shares of IO Biotech Inc (IOBT) were sold and 5,637,029 shares were bought by its insiders, resulting in a net purchase of 4,244,411 shares.

IO Biotech Inc (IOBT)'s detailed insider trading history can be found in Insider Trading Tracker table.

IO Biotech Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Devin Whittemore Smith is the SVP and General Counsel of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

Over the past 18 months, Devin Whittemore Smith made no insider transaction in Kineta Inc (KANT). Other recent insider transactions involving Kineta Inc (KANT) include a net purchase of 7,250 shares made by Raymond J. Bartoszek , a net purchase of 15,000 shares made by Shawn Iadonato , and a net purchase of 10,000 shares made by Keith Baker .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 50,250 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

Devin Whittemore Smith Mailing Address

Above is the net worth, insider trading, and ownership report for Devin Whittemore Smith. You might contact Devin Whittemore Smith via mailing address: C/o Minerva Neurosciences, Inc., 1601 Trapelo Road, Suite 286, Waltham Ma 02451.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.